share_log

What's Going On With Recursion Pharmaceuticals Stock Monday?

What's Going On With Recursion Pharmaceuticals Stock Monday?

週一,Recursion藥品股票怎麼了?
Benzinga ·  06/24 17:12

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares traded higher Monday after the company provided updated guidance and partnership updates at its Investor Day. The stock is continuing to move higher after hours amid a CNBC appearance from CEO Christopher Gibson.

Recursion Pharmaceuticals Inc(NASDAQ: RXRX)股票在投資者日提供更新的指引和合作夥伴更新後交易上漲。在CNBC首席執行官Christopher Gibson的露面之後,股票在交易時段繼續上漲。

What Happened: Recursion provided updated pipeline guidance to investors, analysts and other stakeholders during its Download Day on Monday. The event featured a number of prominent speakers, including NVIDIA Corp (NASDAQ:NVDA) founder and CEO Jensen Huang.

發生了什麼:Recursion在Monday的Download Day上向投資者、分析師和其他利益相關者提供了更新的流水線指導。該活動邀請了許多知名的演講者,包括英偉達創始人兼CEOJensen Huang。

The stock appears to be moving higher in extended trading after Gibson went on CNBC's "Closing Bell: Overtime" just "minutes" before he was set to take the stage with Huang to discuss the role AI will play in drug discovery and development in the future.

股票似乎在盤後交易中上漲,此前Gibson在CNBC“收盤鍾:加班”節目中出現,只有“幾分鐘”就要與Huang一起上臺,討論AI在未來藥物發現和開發中發揮的作用。

Gibson also highlighted that Recursion has built the most powerful supercomputer in the biotech space with the help of Nvidia: BioHive-2.

Gibson還強調,Recursion在Nvidia的幫助下建立了生物技術領域中最強大的超級計算機:BioHive-2。

"We've been able to demonstrate that using these tools, we can roughly three times the speed of discovering and developing medicines towards the clinic and dramatically reduce the costs," Gibson said on the show.

“我們已經能夠證明,使用這些工具,我們可以將發現和開發藥物的速度提高大約三倍,並大幅降低成本,”吉布森在節目中說。

"Ultimately, the most important lever is going to be improving the probability of success ... 90% of drugs that go into clinical trials today fail ... and it's because biology is so complex and machine learning and AI are the right tools when you bring the right data and the right compute to bear to help us make sense and really decode biology."

“最重要的槓桿最終將是提高成功的概率...今天進入臨床試驗的藥物有90%無法成功...這是因爲生物學是如此複雜,當您提供正確的數據和正確的計算方式來幫助我們理解和解碼生物學時,機器學習和AI是正確的工具。”

Nvidia reported investments in multiple companies, including Recursion Pharmaceuticals, in a 13-F filing with the SEC earlier this year. According to the filing, Recursion is Nvidia's second-largest investment after Arm Holdings.

Nvidia在今年早些時候提交給SEC的13-F文件中報告了對多家公司的投資,包括Recursion Pharmaceuticals。根據該文件,Recursion是Nvidia在Arm Holdings之後的第二大投資。

RXRX Price Action: Recursion Pharmaceuticals shares were up 4.50% after hours at $9.34 at the time of publication, according to Benzinga Pro.

RXRX股票價格行情:根據Benzinga Pro的數據,在發佈時,Recursion Pharmaceuticals的股票在盤後交易中上漲了4.50%,爲9.34美元。

Photo: 3844328 from Pixabay.

照片來自Pixabay(ID:3844328)。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論